Physician profile
Carrie Ingram
NPI 1316210263
$15,005.74
in general payments reported to CMS, 2019-2025
30 companies · $3,129 in 2025
The $3,129 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,755 · 2022: $2,915 · 2023: $3,403 · 2024: $3,803 · 2025: $3,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $39.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,295.84 |
| Education | $39.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,731.60 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,259.77 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,247.98 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $1,160.35 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Alkermes, INC. | $1,150.68 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $1,121.36 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $1,112.35 | 2021-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Corium, LLC | $951.40 | 2021-2025 | Azstarys, Adlarity |
| Neurocrine Biosciences, INC. | $842.95 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $815.09 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $437.11 | 2023-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $433.67 | 2022-2024 | Jornay Pm |
| Almatica Pharma LLC | $351.33 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $351.28 | 2023-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Merck Sharp & Dohme LLC | $310.54 | 2021-2023 | Belsomra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $282.03 | 2021-2024 | Sublocade |
| Supernus Pharmaceuticals, INC. | $276.06 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $239.26 | 2022-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $197.99 | 2023-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $181.96 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $141.50 | 2024-2025 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $115.27 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $113.67 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $42.58 | 2021 | |
| Adlon Therapeutics L.P. | $41.26 | 2021 | |
| Braeburn INC. | $21.58 | 2024 | Brixadi |
| Eisai INC. | $21.49 | 2021 | |
| Neos Therapeutics, LP | $18.67 | 2024 | Adzenys Xr-Odt |
| Boston Scientific Corporation | $18.58 | 2021 | |
| Tempus Ai, INC | $16.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.